The role of endovascular therapy in the management of benign prostatic hyperplasia

Tóm tắt

   Benign prostatic hyperplasia is a common condition in elderly men, often associated with lower urinary tract symptoms that negatively impact quality of life. The prevalence of benign prostatic hyperplasia is approximately 8% in men aged 30–40 years, but increases to up to 90% in those over 80 years old. Although current treatment options such as pharmacotherapy and endoscopic surgery have demonstrated high efficacy, surgical interventions still carry a risk of complications, particularly in elderly patients or those with multiple comorbidities. In recent years, prostatic artery embolization has emerged as a minimally invasive treatment modality, in which embolic agents are selectively injected into the prostatic arteries to reduce prostate volume and alleviate symptoms. Initial studies have shown that this endovascular technique offers significant symptom improvement, high treatment efficacy, fewer complications, shorter recovery time, and better quality of life. This review aims to present current medical evidence regarding the efficacy, safety, indications, and potential widespread application of endovascular intervention in the treatment of benign prostatic hyperplasia.

DOI: 10.59715/pntjmp.5.2.1